WHO ICTRP trial
Bioequivalence study of Sertraline 100 mg F.C. Tablet in 24 healthy male under…
IRCT20180620040164N21 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20180620040164N21 |
|---|---|
| Public title | Bioequivalence study of Sertraline 100 mg F.C. Tablet in 24 healthy male under fasting conditions |
| Scientific title | Comparative bioequivalence study of Sertraline 100 mg F.C. Tablet of Dorsa Pharmaceutical Co. and PFIZER Inc. in 24 healthy male under fasting |
| Primary sponsor | Dorsa Pharmaceutical Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | . |
| Interventions | Intervention 1: Intervention group: (test):Sertraline 100 mg F.C. Tablet, produced by Dorsa Pharmaceutical Co. is the test product. In each period, 12 of 24 subjects will be given single oral dose of this product. Intervention 2… |
| Registration date | Feb 20, 2022 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: